Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN to assist with its corporate communications strategy, a move that could significantly increase the company's visibility among investors and the broader financial community. The partnership is particularly important because Apimeds' wholly owned subsidiary, MindWave Innovations, is developing institutional digital asset infrastructure that connects treasury, insurance, tokenized assets, and blockchain ecosystems. This infrastructure is designed to support risk-aware yield on Bitcoin reserves and institutional participation in the digital asset economy.
IBN will leverage its investor-focused distribution network, which includes more than 5,000 syndication outlets, newsletters, social media channels, InvestorWire, and other outreach tools, to generate greater awareness for Apimeds Pharmaceuticals US. The engagement comes at a time when institutional interest in digital assets is growing, and Apimeds is positioning itself to bridge traditional finance with blockchain technology through its MindChain ecosystem. That ecosystem comprises four distinct areas: InsurTech through BlockAssure, which is developing a Bermuda-framework platform applying Bitcoin reserves as regulatory capital to support life and property and casualty underwriting; ClimateTech through AQUAE and the ALCI index, which measures, verifies, and tokenizes ecosystem services into institutional-grade assets; HealthTech through the Apitox development program; and RWA Tech through Nexus Global Partners, which brings institutional real estate on-chain within a compliance-first, insurance-enhanced framework.
The strategic communications support from IBN is expected to help Apimeds communicate these complex initiatives to a wider audience, including potential institutional investors and partners. For a company operating at the intersection of biopharmaceuticals and digital assets, clear and consistent messaging is crucial. Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management, and MindWave Innovations extends its reach into enterprise blockchain infrastructure and institutional technology platforms. By engaging IBN, Apimeds aims to ensure that its dual focus on healthcare and digital asset infrastructure is effectively communicated to the investment community.
For more information on Apimeds, visit www.ApimedsUS.com. To view the full press release, visit https://ibn.fm/PdvmC. The latest news and updates relating to APUS are available in the company's newsroom at https://ibn.fm/APUS.
